LGND
LIGAND PHARMACEUTICALS INC
Nasdaq: LGND · San Diego, CA · Healthcare
$226.67-5.11 (-2.20%)Closed
Market Cap$4.48B
Cash$174.9Mmost recent
Runway21 mo$25.4M Q burn
P/E (TTM)37.0EPS $6.13
52-Wk Range$100.19 – $232.34
Avg Volume201.5K3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$226.67+230.8%
Pipeline

Drug candidates sponsored by LIGAND PHARMACEUTICALS · ClinicalTrials.gov

15 drugs · 21 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 3lasofoxifene
Osteoporosis+1 more
Completed
2007-12past
4
Phase 2Budesonide
Seasonal Allergic Rhinitis
Completed
2007-04past
1
Phase 1MB07133 300mg/m2/day
Hepatocellular Carcinoma
Completed
2007-07past
1
Phase 2MB07803
Type 2 Diabetes Mellitus
Completed
2008-03past
1
Phase 2PS433540
Hypertension
Completed
2008-04past
1
Phase 2Budesonide + Azelastine
Seasonal Allergic Rhinitis
Completed
2008-05past
1
Phase 2Aplindore
Early Stage Parkinson's Disease+1 more
Completed
2008-10past
2
Phase 2irbesartan
Hypertension
Completed
2008-11past
1
Phase 2MB07811
Hypercholesterolemia
Withdrawn
2009-12past
1
Phase 2LGD-6972-5 mg
Type 2 Diabetes Mellitus
Completed
2017-06past
1
Phase 2CE-Iohexol
Contrast-induced Nephropathy
Withdrawn
2023-03past
1
Phase 2Bexarotene
Sarcoma, Kaposi+2 more
Completed—2
Phase 2denileukin diftitox
Drug/Agent Toxicity by Tissue/Organ+1 more
Completed—1
Phase 1LGD-6972
Type 2 Diabetes Mellitus
Completed
2015-05past
2
Phase 1LGD-6972 Solution
Type 2 Diabetes Mellitus (T2DM)
Completed
2016-05past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for LGND. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.